Physician profile
David A Neumann
NPI 1043339575
$8,124.81
in general payments reported to CMS, 2019-2025
35 companies · $2,042 in 2025
The $2,042 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $608 · 2020: $680 · 2021: $746 · 2022: $1,400 · 2023: $1,212 · 2024: $1,437 · 2025: $2,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,589 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,588.87 |
| Education | $102.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,339.81 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $739.20 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $552.13 | 2019-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $309.36 | 2019-2024 | Trulance, Xifaxan |
| Gilead Sciences, INC. | $292.46 | 2019-2025 | |
| Pfizer INC. | $288.44 | 2019-2025 | |
| Genzyme Corporation | $250.75 | 2022-2025 | |
| Celgene Corporation | $245.76 | 2022-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $245.56 | 2020-2021 | |
| Qol Medical, LLC | $235.69 | 2019-2024 | Sucraid, Sucraid |
| Lilly USA, LLC | $212.40 | 2023-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $161.43 | 2022-2025 | Dupixent |
| Daiichi Sankyo INC. | $141.91 | 2019-2023 | Injectafer |
| Ardelyx, INC. | $136.20 | 2022-2023 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $105.41 | 2025 | Iqirvo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Enterra Medical, INC. | $80.00 | 2025 | |
| Ironwood Pharmaceuticals, INC | $78.09 | 2019-2024 | |
| Medtronic, INC. | $76.50 | 2025 | Interstim |
| Redhill Biopharma INC. | $70.10 | 2020-2023 | Movantik, Aemcolo, Talicia |
| Celltrion USA INC. | $69.62 | 2023-2025 | Vegzelma, Yuflyma |
| Intercept Pharmaceuticals, INC. | $61.85 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $57.43 | 2021-2023 | |
| Pharmacosmos Therapeutics INC. | $54.84 | 2023-2025 | Monoferric |
| Shire North American Group INC | $53.95 | 2019 | |
| Aimmune Therapeutics, INC. | $51.73 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $50.33 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $33.22 | 2020-2022 | |
| Ucb, INC. | $31.15 | 2019 | |
| Vivus LLC | $22.87 | 2024 | Qsymia |
| Novo Nordisk INC | $19.51 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $18.33 | 2024 | Dificid |
| Fresenius Kabi USA, LLC | $15.74 | 2023 | |
| Amag Pharmaceuticals, INC. | $12.67 | 2022 | |
| Phathom Pharmaceuticals, INC. | $10.37 | 2025 | Voquezna |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Neumann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.